ACCENTIA BIOPHARMACEUTICALS INC (ABPI) [Rocket]

In millions, except per share items	Dec-31-12	Sep-30-12	Jun-30-12	Mar-31-12	Dec-31-11	Sep-30-11	Jun-30-11	Mar-31-11
	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q
Net Sales:
Products			1.7	1.7
Services			0.4	0.6
Total net sales	2.1	2.1	2.1	2.3	2.3	3.2	0.3	1.7
Total net sales growth	-7.2%	-33.7%	693.1%	34.8%	-11.4%	-40.3%	-89.3%	-83.7%
Cost of sales:
Products			1.0	0.9
Services			0.5	0.5
Total cost of sales (exclusive of amortization of acquired product rights)			1.5	1.4
Gross margin			0.6	0.9
Gross margin			28.2%	37.8%

Operating expenses:
Research and development			2.9	2.5
Sales and marketing			0.1	0.1
General and administrative			5.1	7.0
Total operating expenses			8.2	9.5
Operating loss		-19.1	-28.8	-29.9		-40.2
Operating margin		-901.4%	-1355.5%	-1306.7%		-1257.3%

Other income (expense):
Interest expense			-3.8	-3.8
Derivative gain			-0.2	-0.7
Other (expense) income			0.0	0.0		0.0

Reorganization items:
Professional fees		-0.1	-0.4	-0.4		-0.7
Gain on reorganization			5.5	1.0
Total reorganization items			5.4	1.0
Loss before discontinued operations, income taxes, and non-controlling interest	-18.5	-18.5	-21.9	-28.0	-20.5	-28.2	-59.7	-45.4

Discontinued operations:
Income from discontinued operations				-0.2
Loss before income taxes and non-controlling interest		-15.5	-21.9	-28.0		-27.9
Income taxes			-0.2			-7.6
Tax rate	1.2%	1.2%		-0.2%	-0.3%	26.8%
Net loss		-15.5	-21.9	-28.0		-27.9
Loss from non-controlling interest from variable interest entities and subsidiary			3.2	3.3
Loss attributable to common shareholders	-7.4	-7.4	-14.7	-20.6	-15.4	-20.4	-57.1	-43.9


Per share amounts, basic and diluted
Loss from continuing operations		0.0	0.0	0.0		0.0

Loss attributable to common stockholder		($0.09)	($0.21)	($0.28)		($1.02)